ReviewNPJ precision oncology2025
Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.
Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan.Frontiers in immunology · 2026Pooled it
- Antibody-Drug Conjugates in the Treatment of Esophageal Cancer.Current treatment options in oncology · 2026Review
- PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance.Cancer medicine · 2026Review
- Advances and Future Directions in Antibody-Drug Conjugates: From Paradigm Shifts to Data-Driven Design.Cancers · 2026Review
- Targeting Biliary Tract Cancers with Antibody-Drug Conjugates: Advances in Molecular Targets and Rational Combinations.Cancers · 2026Review
- Glycosylation of B7-H3 Promotes CD8International journal of biological sciences · 2026Article
- Inducing tumor-intrinsic innate immune response to break cancer immunotherapy resistance.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-checkpoint targeting Drug Conjugates (IDCs) are a novel class of therapeutics that combine an immune checkpoint-targeting moiety, a cleavable linker, and a cytotoxic payload. By integrating features and functions of antibody-drug conjugates and immunotherapy, IDCs represent a promising strategy to remodel the tumor microenvironment and enhance antitumor efficacy. Several IDCs targeting checkpoints such as PD-L1, B7-H3, and B7-H4 are in early-phase clinical trials. This review summarizes available data on IDC efficacy and toxicity in human. Although current evidence is limited, ongoing phase III trials and biomarker studies will clarify their optimal clinical role, including potential for tumor-agnostic use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.